Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Thrombolysis, Thrombectomy, or Bridging Therapy for Acute Medium Vessel Occlusion Within 24 Hours: A Multicenter, Three-Arm, Randomized Controlled Trial

NCT07931807 is registered in ClinicalTrials.gov with The First Affiliated Hospital of University of Science and Technology of China as lead sponsor.

NCT NCT07931807 Not yet recruiting Phase 3 1,395 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07931807 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, Phase 3, 1,395 participants (estimated). Lead sponsor The First Affiliated Hospital of University of Science and Technology of China; China. Primary measure: Functional Independence at 90 Days.

How it compares

263 similar trials: same condition (Ischemic Stroke) and phase

Enrollment

This trial
1,395
Middle half
222 to 982
Median
520
Trials with a value
263

Months from start to completion

This trial
28
Middle half
22 to 45.2
Median
29.8
Trials with a value
256

Sites

This trial
1
Middle half
1 to 22
Median
1
Trials with a value
241
Posted results or a linked paper 56% 148 of 263 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Thrombolysis, Thrombectomy, or Bridging Therapy for Acute Medium Vessel Occlusion Within 24 Hours: A Multicenter, Three-Arm, Randomized Controlled Trial
Lead sponsor
The First Affiliated Hospital of University of Science and Technology of China
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
April 30, 2029
Enrollment
1,395 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Ischemic Stroke

Registry terms: acute ischemic stroke, medium vessel occlusion stroke (mevo)

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
1
Countries
China
Lead sponsor
The First Affiliated Hospital of University of Science and Technology of China

Arms

As registered; 3 arms.

Registered arms
Arm Type Interventions
IVT Alone Active comparator Tenecteplase
Show registry wording

Participants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus. Endovascular treatment is not performed.

EVT Alone Experimental Endovascular Treatment
Show registry wording

Participants receive endovascular treatment without intravenous thrombolysis.

Bridging IVT Plus EVT Experimental Endovascular Treatment, Tenecteplase
Show registry wording

Participants receive intravenous tenecteplase 0.25 mg/kg (maximum 25 mg) as a single bolus, followed immediately by endovascular treatment.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Functional Independence at 90 Days 90 days after randomization (±14 days)
Show registry wording

Proportion of participants with a modified Rankin Scale (mRS) score of 0 to 2 at 90 days, assessed by a blinded rater. The mRS ranges from 0 (no symptoms) to 6 (death).

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Tenecteplase 1 Orange Book patent
    • US 5385732; expires June 2, 2014; assignee Genentech

Lead sponsor's other trials

The First Affiliated Hospital of University of Science and Technology of China, most recent start first.

Similar trials

Same condition (Ischemic Stroke) and phase, most recent start first.